Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).

[1]  R. Kaji,et al.  Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins. , 2010, Toxicon : official journal of the International Society on Toxinology.

[2]  V. Tugnoli,et al.  Botulinum Toxin for Pain , 2008, Drugs in R&D.

[3]  D. Sesardic,et al.  A review of WHO International Standards for botulinum antitoxins. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[4]  W. Jost,et al.  Botulinum toxin: clinical use. , 2006, Parkinsonism & related disorders.

[5]  J. Jankovic,et al.  Botulinum toxin in clinical practice , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  Dorothea Sesardic,et al.  Detection of antibodies against botulinum toxins , 2004, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Dressler.  Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[8]  Roberto Eleopra,et al.  Different types of botulinum toxin in humans , 2004, Movement disorders : official journal of the Movement Disorder Society.

[9]  S. Kozaki,et al.  Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. , 2002, Vaccine.

[10]  V. Tugnoli,et al.  Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans , 1998, Neuroscience Letters.

[11]  Leonard A. Smith,et al.  Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.

[12]  R. Benecke,et al.  The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .

[13]  M. Goodnough,et al.  Botulinum toxin therapy, immunologic resistance, and problems with available materials , 1996, Neurology.

[14]  M. Brin,et al.  Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm , 1995, Neurology.

[15]  J. Snyder,et al.  Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. , 1984, The Journal of infectious diseases.

[16]  G. Sakaguchi,et al.  PURIFICATION AND ORAL TOXICITIES OF CLOSTRIDIUM BOTULINUM PROGENITOR TOXINS , 1981 .